BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36794424)

  • 1. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?
    Nguyen Quoc A; Beccaria K; González Briceño L; Pinto G; Samara-Boustani D; Stoupa A; Beltrand J; Besançon A; Thalassinos C; Puget S; Blauwblomme T; Alapetite C; Bolle S; Doz F; Grill J; Dufour C; Bourdeaut F; Abbou S; Guerrini-Rousseau L; Leruste A; Brabant S; Cavadias I; Viaud M; Boddaert N; Polak M; Kariyawasam D
    J Clin Endocrinol Metab; 2023 Jul; 108(8):1929-1936. PubMed ID: 36794424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence.
    Losa M; Castellino L; Pagnano A; Rossini A; Mortini P; Lanzi R
    J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 32112101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Growth Hormone Replacement Therapy in Childhood-Onset Craniopharyngioma: A Systematic Review and Cohort Study.
    van Schaik J; Kormelink E; Kabak E; van Dalen EC; Schouten-van Meeteren AYN; de Vos-Kerkhof E; Bakker B; Fiocco M; Hoving EW; Tissing WJE; van Santen HM
    Neuroendocrinology; 2023; 113(10):987-1007. PubMed ID: 37231961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study.
    Smith TR; Cote DJ; Jane JA; Laws ER
    J Neurosurg Pediatr; 2016 Oct; 18(4):408-412. PubMed ID: 27286443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up.
    Olsson DS; Buchfelder M; Wiendieck K; Kremenevskaja N; Bengtsson BÅ; Jakobsson KE; Jarfelt M; Johannsson G; Nilsson AG
    Eur J Endocrinol; 2012 Jun; 166(6):1061-8. PubMed ID: 22457235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma.
    Karavitaki N; Warner JT; Marland A; Shine B; Ryan F; Arnold J; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2006 May; 64(5):556-60. PubMed ID: 16649976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologic Growth Hormone-Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis.
    Alotaibi NM; Noormohamed N; Cote DJ; Alharthi S; Doucette J; Zaidi HA; Mekary RA; Smith TR
    World Neurosurg; 2018 Jan; 109():487-496.e1. PubMed ID: 28987837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and risks evaluation of recombinant human growth hormone replacement therapy in children with GHD after craniopharyngioma surgery.
    Pei LL; Guo Y; Chen H; Zhong LY
    J Pediatr Endocrinol Metab; 2023 May; 36(5):484-491. PubMed ID: 36935568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analyses of treatment variables for patients with childhood craniopharyngioma--results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-up.
    Müller HL; Gebhardt U; Schröder S; Pohl F; Kortmann RD; Faldum A; Zwiener I; Warmuth-Metz M; Pietsch T; Calaminus G; Kolb R; Wiegand C; Sörensen N;
    Horm Res Paediatr; 2010; 73(3):175-80. PubMed ID: 20197669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety of growth hormone replacement after CNS irradiation.
    Mackenzie S; Craven T; Gattamaneni HR; Swindell R; Shalet SM; Brabant G
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2756-61. PubMed ID: 21715535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy.
    Holmer H; Ekman B; Björk J; Nordstöm CH; Popovic V; Siversson A; Erfurth EM
    Eur J Endocrinol; 2009 Nov; 161(5):671-9. PubMed ID: 19667040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy.
    Olsson DS; Buchfelder M; Schlaffer S; Bengtsson BA; Jakobsson KE; Johannsson G; Nilsson AG
    Eur J Endocrinol; 2009 Nov; 161(5):663-9. PubMed ID: 19734242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy.
    Gasco V; Caputo M; Cambria V; Beccuti G; Caprino MP; Ghigo E; Maccario M; Grottoli S
    Endocrine; 2019 Feb; 63(2):341-347. PubMed ID: 30341707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex Differences in Long-Term Safety and Tolerability of GH Replacement Therapy in GH Deficient Adults.
    Slagboom TNA; van Bunderen CC; van der Lely AJ; Drent ML
    J Clin Endocrinol Metab; 2023 Jun; 108(7):e415-e424. PubMed ID: 36652411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Effects of Growth Hormone Replacement Therapy in Childhood-onset Craniopharyngioma: Results of the German Craniopharyngioma Registry (HIT-Endo).
    Boekhoff S; Bogusz A; Sterkenburg AS; Eveslage M; Müller HL
    Eur J Endocrinol; 2018 Oct; 179(5):331-341. PubMed ID: 30139824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with craniopharyngiomas: therapeutical difficulties with growth hormone.
    Cannavò S; Marini F; Trimarchi F
    J Endocrinol Invest; 2008 Sep; 31(9 Suppl):56-60. PubMed ID: 19020388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Childhood-onset Craniopharyngioma in Italy: A Multicenter, 7-Year Follow-up Study of 145 Patients.
    Zucchini S; Di Iorgi N; Pozzobon G; Pedicelli S; Parpagnoli M; Driul D; Matarazzo P; Baronio F; Crocco M; Iudica G; Partenope C; Nardini B; Ubertini G; Menardi R; Guzzetti C; Iughetti L; Aversa T; Di Mase R; Cassio A;
    J Clin Endocrinol Metab; 2022 Feb; 107(3):e1020-e1031. PubMed ID: 34718649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone therapy and risk of recurrence/progression in intracranial tumors: a meta-analysis.
    Shen L; Sun CM; Li XT; Liu CJ; Zhou YX
    Neurol Sci; 2015 Oct; 36(10):1859-67. PubMed ID: 26048536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoscopic endonasal approach for craniopharyngioma: the importance of the relationship between pituitary stalk and tumor.
    Dho YS; Kim YH; Se YB; Han DH; Kim JH; Park CK; Wang KC; Kim DG
    J Neurosurg; 2018 Sep; 129(3):611-619. PubMed ID: 28960155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of growth hormone treatment in children with craniopharyngioma with reference to the KIGS (Kabi International Growth Study) database.
    Price DA; Jönsson P
    Acta Paediatr Suppl; 1996 Oct; 417():83-5. PubMed ID: 9055921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.